

Anthony Dorling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8666101/publications.pdf>

Version: 2024-02-01

123
papers

3,889
citations

109321

35
h-index

149698

56
g-index

127
all docs

127
docs citations

127
times ranked

3709
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of T- and B-cell interactions determines the clinical phenotype associated with donor-specific antibodies. <i>Kidney International</i> , 2022, 101, 877-879.	5.2	2
2	The phenotype of HLA-binding B cells from sensitized kidney transplant recipients correlates with clinically prognostic patterns of interferon- γ production against purified HLA proteins. <i>Kidney International</i> , 2022, 102, 355-369.	5.2	4
3	B lymphocytes contribute to indirect pathway T cell sensitization via acquisition of extracellular vesicles. <i>American Journal of Transplantation</i> , 2021, 21, 1415-1426.	4.7	12
4	PAR-1 signaling on macrophages is required for effective in vivo delayed-type hypersensitivity responses. <i>IScience</i> , 2021, 24, 101981.	4.1	7
5	Effect of delayed graft function on longer-term outcomes after kidney transplantation from donation after circulatory death donors in the United Kingdom: A national cohort study. <i>American Journal of Transplantation</i> , 2021, 21, 3346-3355.	4.7	27
6	A multicenter randomized controlled trial indicates that paclitaxel-coated balloons provide no benefit for arteriovenous fistulas. <i>Kidney International</i> , 2021, 100, 447-456.	5.2	30
7	Paclitaxel-assisted balloon angioplasty of venous stenosis in haemodialysis access: PAVE RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-36.	0.7	1
8	Effect of rituximab on anti-donor T cell responses. <i>Transplant International</i> , 2020, 33, 1322-1323.	1.6	1
9	Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts. <i>Frontiers in Immunology</i> , 2020, 11, 79.	4.8	16
10	Regression of Atherosclerosis in ApoE ^{-/-} Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel Cytotoxic Anti-Thrombin Without Prolonged Anticoagulation. <i>Journal of the American Heart Association</i> , 2020, 9, e014811.	3.7	8
11	Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 612848.	4.8	10
12	Update to the study protocol, including statistical analysis plan, for the multicentre, randomised controlled OutSMART trial: a combined screening/treatment programme to prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies. <i>Trials</i> , 2019, 20, 476.	1.6	4
13	Regulatory B cells: Development, phenotypes, functions, and role in transplantation. <i>Immunological Reviews</i> , 2019, 292, 164-179.	6.0	46
14	Protease Activated Receptor 4 as a Novel Modulator of Regulatory T Cell Function. <i>Frontiers in Immunology</i> , 2019, 10, 1311.	4.8	12
15	Clinical pathological correlations in post-transplant thrombotic microangiopathy. <i>Histopathology</i> , 2019, 75, 88-103.	2.9	16
16	For the many: permitting deceased donor kidney transplantation across low-titre blood group antibodies can reduce wait times for blood group B recipients, and improve the overall number of transplants a multicentre observational cohort study. <i>Transplant International</i> , 2019, 32, 431-442.	1.6	7
17	Endothelial cell-specific anticoagulation reduces inflammation in a mouse model of acute lung injury. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 769-780.	6.1	17
18	Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. <i>Transplantation Reviews</i> , 2018, 32, 119-126.	2.9	12

#	ARTICLE	IF	CITATIONS
19	Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies. <i>Pediatric Nephrology</i> , 2018, 33, 167-174.	1.7	17
20	Inhibition of Angiopoietin-2 Production by Myofibrocytes Inhibits Neointimal Hyperplasia After Endoluminal Injury in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 1517.	4.8	6
21	Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. <i>Lancet, The</i> , 2017, 389, 727-734.	13.7	82
22	Transitional B cell subsetsâ€”a convincing predictive biomarker for allograft loss?. <i>Kidney International</i> , 2017, 91, 18-20.	5.2	5
23	Graft dysfunction in chronic antibody-mediated rejection correlates with B-cellâ€”dependent indirect antidonor alloresponses and autocrine regulation of interferon- γ production by Th1 cells. <i>Kidney International</i> , 2017, 91, 477-492.	5.2	34
24	Thrombalexins: Cell-Localized Inhibition of Thrombin and Its Effects in a Model of High-Risk Renal Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 272-280.	4.7	13
25	Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 241.	1.6	28
26	APT070 (mirococept), a membraneâ€”localizing C3 convertase inhibitor, attenuates early human islet allograft damage <i>in vitro</i> and <i>in vivo</i> in a humanized mouse model. <i>British Journal of Pharmacology</i> , 2016, 173, 575-587.	5.4	19
27	Organ Pretreatment With Cytotoxic Endothelial Localizing Peptides to Ameliorate Microvascular Thrombosis and Perfusion Deficits in Ex Vivo Renal Hemoreperfusion Models. <i>Transplantation</i> , 2016, 100, e128-e139.	1.0	31
28	Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations. <i>Transplant International</i> , 2015, 28, 1205-1215.	1.6	29
29	Incidence and Outcome of C4d Staining With Tubulointerstitial Inflammation in Blood Group-incompatible Kidney Transplantation. <i>Transplantation</i> , 2015, 99, 1487-1494.	1.0	13
30	Expression of Human Tissue Factor Pathway Inhibitor on Vascular Smooth Muscle Cells Inhibits Secretion of Macrophage Migration Inhibitory Factor and Attenuates Atherosclerosis in ApoE \sim/\sim Mice. <i>Circulation</i> , 2015, 131, 1350-1360.	1.6	36
31	B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection. <i>Kidney International</i> , 2015, 88, 560-568.	5.2	42
32	Role of <i>P</i> -selectin and <i>P</i> -selectin glycoprotein ligandâ€”1 interaction in the induction of tissue factor expression on human platelets after incubation with porcine aortic endothelial cells. <i>Xenotransplantation</i> , 2014, 21, 16-24.	2.8	14
33	Optimising long-term graft survival: establishing the benefit of targeting B lymphocytes. <i>Clinical Medicine</i> , 2014, 14, s84-s88.	1.9	2
34	Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial. <i>Trials</i> , 2014, 15, 30.	1.6	8
35	Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation. <i>Transplant International</i> , 2014, 27, 187-196.	1.6	75
36	Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2 γ null Mice. <i>PLoS ONE</i> , 2014, 9, e90387.	2.5	50

#	ARTICLE	IF	CITATIONS
37	Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: Specific inhibition of thrombocytopenia. <i>Thrombosis Research</i> , 2013, 132, 750-756.	1.7	3
38	A new and clinically relevant murine model of solid-organ transplant aspergillosis. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 643-51.	2.4	31
39	The use of eculizumab in renal transplantation. <i>Clinical Transplantation</i> , 2013, 27, E216-29.	1.6	47
40	Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4 ⁺ T cell priming. <i>Immunology</i> , 2013, 139, 219-226.	4.4	12
41	Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 963-974.	3.8	10
42	Inhibition of Thrombin Receptor Signaling on β -Smooth Muscle Actin + CD34 + Progenitors Leads to Repair After Murine Immune Vascular Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 42-49.	2.4	10
43	Renal Allograft Recipients Fail to Increase Interferon- β During Invasive Fungal Diseases. <i>American Journal of Transplantation</i> , 2012, 12, 3437-3440.	4.7	15
44	Transplant Accommodation: Are the Lessons Learned from Xenotransplantation Pertinent for Clinical Allograft Transplantation?. <i>American Journal of Transplantation</i> , 2012, 12, 545-553.	4.7	25
45	Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation. <i>Transplant International</i> , 2012, 25, 882-896.	1.6	22
46	The roles of thrombin and protease-activated receptors in inflammation. <i>Seminars in Immunopathology</i> , 2012, 34, 63-72.	6.1	61
47	Pancreatic-Derived Pathfinder Cells Enable Regeneration of Critically Damaged Adult Pancreatic Tissue and Completely Reverse Streptozotocin-Induced Diabetes. <i>Rejuvenation Research</i> , 2011, 14, 163-171.	1.8	15
48	Smooth muscle cells in porcine vein graft intimal hyperplasia are derived from the local vessel wall. <i>Cardiovascular Pathology</i> , 2011, 20, e91-e94.	1.6	12
49	Plasmapheresis as rescue therapy for systemic lupus erythematosus-associated diffuse alveolar haemorrhage. <i>BMJ Case Reports</i> , 2011, 2011, bcr0220113893-bcr0220113893.	0.5	17
50	Kidney Transplantation With Minimized Maintenance: Alemtuzumab Induction With Tacrolimus Monotherapy: An Open Label, Randomized Trial. <i>Transplantation</i> , 2011, 92, 774-780.	1.0	49
51	Antibody-Mediated Rejection After Alemtuzumab Induction: Incidence, Risk Factors, and Predictors of Poor Outcome. <i>Transplantation</i> , 2011, 92, 176-182.	1.0	45
52	Outcome of Patients with Preformed Donor-Specific Antibodies Following Alemtuzumab Induction and Tacrolimus Monotherapy. <i>American Journal of Transplantation</i> , 2011, 11, 470-477.	4.7	52
53	B cells in renal transplantation: pathological aspects and therapeutic interventions. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 767-774.	0.7	15
54	Exogenous Interferon- β Immunotherapy for Invasive Fungal Infections in Kidney Transplant Patients. <i>American Journal of Transplantation</i> , 2010, 10, 1796-1803.	4.7	91

#	ARTICLE	IF	CITATIONS
55	Recipient Tissue Factor Expression Is Associated With Consumptive Coagulopathy in Pig-to-Primate Kidney Xenotransplantation. <i>American Journal of Transplantation</i> , 2010, 10, 1556-1568.	4.7	100
56	Rituximab May Not Lead to Increased Infection Rates in Transplant Recipients. <i>American Journal of Transplantation</i> , 2010, 10, 2723-2724.	4.7	3
57	Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-human Gal IgG binding to porcine aortic endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2001-2010.	3.8	48
58	Critical roles for thrombin in acute and chronic inflammation. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 122-126.	3.8	91
59	Current status of xenotransplantation and prospects for clinical application. <i>Xenotransplantation</i> , 2009, 16, 263-280.	2.8	126
60	Coagulation dysregulation as a barrier to xenotransplantation in the primate. <i>Transplant Immunology</i> , 2009, 21, 75-80.	1.2	70
61	Regulation of Rat and Human T-Cell Immune Response by Pharmacologically Modified Dendritic Cells. <i>Transplantation</i> , 2009, 87, 1617-1628.	1.0	15
62	Donor HO-1 Expression Inhibits Intimal Hyperplasia in Unmanipulated Graft Recipients: A Potential Role for CD8+ T-Cell Modulation by Carbon Monoxide. <i>Transplantation</i> , 2009, 88, 653-661.	1.0	18
63	Progenitor cells and vascular disease. <i>Cell Proliferation</i> , 2008, 41, 146-164.	5.3	25
64	A pig allograft model of antibody-mediated rejection. <i>Transplant Immunology</i> , 2008, 19, 167-172.	1.2	2
65	Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. <i>Journal of Experimental Medicine</i> , 2008, 205, 1739-1746.	8.5	81
66	Expression of Tissue Factor and Initiation of Clotting by Human Platelets and Monocytes After Incubation With Porcine Endothelial Cells. <i>Transplantation</i> , 2008, 86, 702-709.	1.0	67
67	Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors. <i>Blood</i> , 2008, 111, 4155-4164.	1.4	19
68	ABO Incompatible Living Renal Transplantation With a Steroid Sparing Protocol. <i>Transplantation</i> , 2008, 86, 901-906.	1.0	35
69	Extraanatomic stents for transplant ureteric stenosis. <i>British Journal of Radiology</i> , 2007, 80, 216-218.	2.2	9
70	±1,3-Galactosyltransferase Gene-Knockout Pigs for Xenotransplantation: Where Do We Go From Here?. <i>Transplantation</i> , 2007, 84, 1-7.	1.0	83
71	Reply to 'Critics slam Russian trial to test pig pancreas for diabetes'. <i>Nature Medicine</i> , 2007, 13, 662-663.	30.7	7
72	Response to Valdes-Gonzalez "Clinical trial of islet xenotransplantation in Mexico". <i>Xenotransplantation</i> , 2007, 14, 90-91.	2.8	8

#	ARTICLE	IF	CITATIONS
73	The Interface Between Coagulation and Immunity. American Journal of Transplantation, 2007, 7, 499-506.	4.7	43
74	NK-cell-dependent acute xenograft rejection in the mouse heart-to-rat model. Xenotransplantation, 2006, 13, 408-414.	2.8	28
75	Clinical trial of islet xenotransplantation in Mexico. Xenotransplantation, 2006, 13, 371-372.	2.8	18
76	Postinjury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins. Journal of Thrombosis and Haemostasis, 2006, 4, 2191-2198.	3.8	19
77	All anti-HBc-positive, HBsAg-negative dialysis patients on the transplant waiting list should be regarded as at risk of hepatitis B reactivation post-renal transplantation-report of three cases from a single centre. Nephrology Dialysis Transplantation, 2006, 21, 3316-3319.	0.7	17
78	Tolerance or Accommodation: The Lesson from Leflunomide. Transplantation, 2005, 79, 133-134.	1.0	3
79	Microcoagulation processes after xenotransplantation. Current Opinion in Organ Transplantation, 2005, 10, 240-245.	1.6	18
80	Cure of Disseminated Cryptococcal Infection in a Renal Allograft Recipient After Addition of gamma-Interferon to Anti-Fungal Therapy. American Journal of Transplantation, 2005, 5, 2067-2069.	4.7	22
81	Generation of a polyclonal rabbit anti-mouse tissue factor antibody by nucleic acid immunisation. Thrombosis and Haemostasis, 2005, 93, 160-164.	3.4	6
82	Achieving Permanent Survival of Islet Xenografts by Independent Manipulation of Direct and Indirect T-Cell Responses. Diabetes, 2005, 54, 1048-1055.	0.6	47
83	Modified Dendritic Cells Coexpressing Self and Allogeneic Major Histocompatibility Complex Molecules: An Efficient Way to Induce Indirect Pathway Regulation. Journal of the American Society of Nephrology: JASN, 2004, 15, 987-997.	6.1	102
84	Complete Inhibition of Acute Humoral Rejection Using Regulated Expression of Membrane-tethered Anticoagulants on Xenograft Endothelium. American Journal of Transplantation, 2004, 4, 1958-1963.	4.7	93
85	DEVELOPING A PORCINE TRANSPLANTATION MODEL: EFFICIENT GENE TRANSFER INTO PORCINE VASCULAR CELLS. Transplantation, 2004, 77, 1443-1451.	1.0	5
86	Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood, 2004, 104, 1344-1349.	1.4	49
87	Transplant Accommodation. American Journal of Transplantation, 2003, 3, 917-918.	4.7	13
88	Endothelial cell cytoprotection induced in vitro by allo- or xenoreactive antibodies is mediated by signaling through adenosine A2 receptors. European Journal of Immunology, 2003, 33, 3127-3135.	2.9	31
89	Are anti-endothelial cell antibodies a pre-requisite for the acute vascular rejection of xenografts?. Xenotransplantation, 2003, 10, 16-23.	2.8	30
90	The cellular rejection of xenografts - recent insights. Xenotransplantation, 2003, 10, 4-6.	2.8	21

#	ARTICLE	IF	CITATIONS
91	Cross-species costimulation: relative contributions of CD80, CD86, and CD40. <i>Transplantation</i> , 2003, 75, 2068-2076.	1.0	28
92	Clinical Xenotransplantation: Pigs Might Fly?. <i>American Journal of Transplantation</i> , 2002, 2, 695-700.	4.7	32
93	Immunosuppression of direct T-cell-mediated xenorecognition in vitro. <i>Transplantation Proceedings</i> , 2001, 33, 697-698.	0.6	1
94	Disordered thromboregulation after xenografting. <i>Current Opinion in Organ Transplantation</i> , 2001, 6, 36-41.	1.6	12
95	NITRIC OXIDE-MEDIATED EXPRESSION OF Bcl-2 AND Bcl-xl AND PROTECTION FROM TUMOR NECROSIS FACTOR- α -MEDIATED APOPTOSIS IN PORCINE ENDOTHELIAL CELLS AFTER EXPOSURE TO LOW CONCENTRATIONS OF XENOREACTIVE NATURAL ANTIBODY1. <i>Transplantation</i> , 2001, 71, 599-605.	1.0	54
96	ACCOMMODATED PIG ENDOTHELIAL CELLS PROMOTE NITRIC OXIDE-DEPENDENT Th-2 CYTOKINE RESPONSES FROM HUMAN T CELLS1. <i>Transplantation</i> , 2001, 72, 1597-1602.	1.0	8
97	Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. <i>Xenotransplantation</i> , 2001, 8, 258-265.	2.8	17
98	Transplant Accommodation in Highly Sensitized Patients: A Potential Role for Bcl-xL and Alloantibody. <i>American Journal of Transplantation</i> , 2001, 1, 260-269.	4.7	163
99	EXPRESSION OF NOVEL ANTICOAGULANT FUSION PROTEINS INHIBITS FACTOR XA- AND THROMBIN-INDUCED ACTIVATION OF PORCINE VASCULAR ENDOTHELIAL CELLS.. <i>Transplantation</i> , 2000, 69, S383.	1.0	2
100	CLONING OF PORCINE INTERCELLULAR ADHESION MOLECULE-1 AND CHARACTERIZATION OF ITS INDUCTION ON ENDOTHELIAL CELLS BY CYTOKINES1. <i>Transplantation</i> , 2000, 70, 579-586.	1.0	21
101	HLA-G inhibits the transendothelial migration of human NK cells. <i>European Journal of Immunology</i> , 2000, 30, 586-593.	2.9	88
102	Costimulatory blockade by the induction of an endogenous xenospecific antibody response. <i>Nature Immunology</i> , 2000, 1, 163-168.	14.5	27
103	Porcine CTLA4-Ig Lacks a MYPPPY Motif, Binds Inefficiently to Human B7 and Specifically Suppresses Human CD4+ T Cell Responses Costimulated by Pig But Not Human B7. <i>Journal of Immunology</i> , 2000, 165, 3175-3181.	0.8	51
104	HLA-G inhibits the transendothelial cell migration of human NK cells: a strategy for inhibiting xenograft rejection. <i>Transplantation Proceedings</i> , 2000, 32, 938.	0.6	21
105	Regulated endothelial cell expression of novel anticoagulants: a strategy for the prevention and therapy of intravascular thrombosis. <i>Transplantation Proceedings</i> , 2000, 32, 971.	0.6	1
106	HLA-G inhibits the transendothelial migration of human NK cells. , 2000, 30, 586.		3
107	Phenotypic Characterization of Histiocytes Infiltrating a Leiomyofibrosarcoma. <i>Journal of Comparative Pathology</i> , 1999, 120, 177-186.	0.4	0
108	INHIBITION OF TISSUE FACTOR-DEPENDENT AND -INDEPENDENT COAGULATION BY CELL SURFACE EXPRESSION OF NOVEL ANTICOAGULANT FUSION PROTEINS. <i>Transplantation</i> , 1999, 67, 467-474.	1.0	35

#	ARTICLE	IF	CITATIONS
109	REGULATED INHIBITION OF COAGULATION BY PORCINE ENDOTHELIAL CELLS EXPRESSING P-SELECTIN-TAGGED HIRUDIN AND TISSUE FACTOR PATHWAY INHIBITOR FUSION PROTEINS. <i>Transplantation</i> , 1999, 68, 832-839.	1.0	42
110	In vitro accommodation of porcine endothelial cells by low dose human anti-pig antibody: Reduced binding of human lymphocytes by accommodated cells associated with increased nitric oxide production. <i>Xenotransplantation</i> , 1998, 5, 84-92.	2.8	28
111	T cell-mediated xenograft rejection: Specific tolerance is probably required for long term xenograft survival. <i>Xenotransplantation</i> , 1998, 5, 234-245.	2.8	67
112	Expression of Hirudin Fusion Proteins in Mammalian Cells. <i>Circulation</i> , 1998, 98, 2744-2752.	1.6	31
113	Xenotransplantation: Immune Barriers beyond Hyperacute Rejection. <i>Clinical Science</i> , 1997, 93, 493-505.	4.3	7
114	Strategies for preventing porcine xenograft rejection: recent progress and future developments. Expert Opinion on Therapeutic Patents, 1997, 7, 1307-1319.	5.0	4
115	Clinical xenotransplantation of solid organs. <i>Lancet</i> , The, 1997, 349, 867-871.	13.7	78
116	Human Tissue Factor Pathway Inhibitor Fused to CD4 Binds both FXa and TF/FVIIa at the Cell Surface. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1488-1494.	3.4	19
117	Cellular xenoresponses: Observation of significant primary indirect human T cell anti-pig xenoresponses using co-stimulator-deficient or SLA class II-negative porcine stimulators. <i>Xenotransplantation</i> , 1996, 3, 112-119.	2.8	25
118	Cellular xenoresponses: Although vigorous, direct human T cell anti-pig primary xenoresponses are significantly weaker than equivalent alloresponses. <i>Xenotransplantation</i> , 1996, 3, 149-157.	2.8	21
119	Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. <i>European Journal of Immunology</i> , 1996, 26, 1378-1387.	2.9	112
120	Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. <i>Journal of Experimental Medicine</i> , 1996, 183, 1603-1612.	8.5	121
121	IN VITRO ACCOMMODATION OF IMMORTALIZED PORCINE ENDOTHELIAL CELLS. <i>Transplantation</i> , 1996, 62, 1127-1136.	1.0	81
122	Prospects for xenografting. <i>Current Opinion in Immunology</i> , 1994, 6, 765-769.	5.5	35
123	Genetically Engineering a Pig that Minimizes Coagulation Incompatibilities. <i>Graft: Organ and Cell Transplantation</i> , 0, 4, 72-75.	0.0	1